EPO and myelodysplastic syndrome: In the phase 3 study of EPO in ESA-naïve LR MDS patients with a low transfusion burden (TB), the response rate was higher in the EPO arm compared to placebo (31.8% vs. 4.4%, p < 0.001); all responders had sEPO < 200 U/L [52].